Tislelizumab as Cross-line Treatment for Advanced NSCLC

NCT05192681 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER_GOV

Sponsor class

Conditions

Advanced Non-small-cell Lung Cancer

Interventions

DRUG: Tislelizumab

Sponsor

Fujian Cancer Hospital